Sino Biopharmaceutical's Phase-3 Trial of Breast Cancer Drug Reaches Primary Endpoint

Sino Biopharmaceutical's (HKG:1177) interim analysis of a phase III clinical trial of its Culmerciclib capsule combined with the Fulvestrant injection has met the default primary endpoints, a

MT NewswiresJul 18 06:34 ET

Sino Biopharm (01177) under the Hong Kong stock connect program: Phase III clinical trials related to breast cancer treatment achieve the predetermined primary endpoint.

Sinobiopharm (01177) announced that the phase III clinical trial (NCT05375461) of type 1 innovative drug Culmerciclib (TQB3616) developed by the group and combined with fluvisinque injection for the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer that has been treated with endocrine therapy in the past has completed mid-term analysis and has achieved the preset primary endpoint after being reviewed by the Independent Data Monitoring Committee (IDMC). The research results will be published in academic journals or major academic conferences.

金吾財訊Jul 18 04:37 ET

Sino Biopharm (01177.HK): The new drug application for Class 1 innovative drug Culmerciclib (TQB3616) has been accepted for listing.

Sino Biopharm (01177.HK) announced that the Phase III clinical trial (NCT05375461) of the class 1 innovative drug Culmerciclib (TQB3616) developed by the group, combined with Fluvisumab injection for the treatment of Hormone Receptor (HR)-positive and Human Epidermal Growth Factor Receptor 2 (HER2)-negative locally advanced or metastatic breast cancer previously treated with endocrine therapy, has completed mid-term analysis and achieved the preset primary endpoint after being reviewed by the Independent Data Monitoring Committee (IDMC). The research results will be published in academic journals or major publications.

Gelonghui FinanceJul 18 04:35 ET

Express News | Sino Biopharmaceutical - Acceptance by National Medical Products Administration

ReutersJul 18 04:32 ET

Express News | Sino Biopharmaceutical - Acceptance of New Drug Application for Category 1 Innvoative Drug Culmerciclib Capsule Culmerciclib (Tqb3616)

ReutersJul 18 04:32 ET

Sino Biopharmaceutical Soft Tissue Sarcoma Drug Gives Positive Phase III Trial Results

Sino Biopharmaceutical (HKG:1177) said its Advanced Soft Tissue Sarcoma drug obtained the CDE's consent to submit a marketing application in combination with chemotherapy, according to a Tuesday

MT NewswiresJul 17 04:12 ET